Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
In the latest session, Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) closed at $64.8 up 0.22% from its previous closing price of $64.66. In other words, the price has increased by $0.22 from its previous closing price. On the day, 2.18 million shares were traded. ARWR stock price reached its highest trading level at $67.3 during the session, while it also had its lowest trading level at $63.01.
Ratios:
For a deeper understanding of Arrowhead Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.57 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 56.09. For the most recent quarter (mrq), Quick Ratio is recorded 4.86 and its Current Ratio is at 4.86. In the meantime, Its Debt-to-Equity ratio is 1.57 whereas as Long-Term Debt/Eq ratio is at 1.47.
Upgrades & Downgrades
In the most recent recommendation for this company, Goldman on June 05, 2024, initiated with a Neutral rating and assigned the stock a target price of $31.
On December 04, 2023, BofA Securities started tracking the stock assigning a Buy rating and target price of $29.
On September 19, 2023, Citigroup started tracking the stock assigning a Neutral rating and target price of $33.Citigroup initiated its Neutral rating on September 19, 2023, with a $33 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 17 ’25 when Christopher Anzalone bought 85,000 shares for $64.04 per share.
Christopher Anzalone bought 54,298 shares of ARWR for $3,398,142 on Dec 16 ’25. On Dec 15 ’25, another insider, Anzalone Christopher Richard, who serves as the Chief Executive Officer of the company, sold 130,000 shares for $68.85 each. As a result, the insider received 8,950,615 and left with 3,971,255 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARWR now has a Market Capitalization of 8959089664 and an Enterprise Value of 8654038016. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.61 while its Price-to-Book (P/B) ratio in mrq is 18.87. Its current Enterprise Value per Revenue stands at 10.433 whereas that against EBITDA is 70.776.
Stock Price History:
The Beta on a monthly basis for ARWR is 1.21, which has changed by 2.3158975 over the last 52 weeks, in comparison to a change of 0.15905356 over the same period for the S&P500. Over the past 52 weeks, ARWR has reached a high of $72.36, while it has fallen to a 52-week low of $9.57. The 50-Day Moving Average of the stock is 38.46%, while the 200-Day Moving Average is calculated to be 153.86%.
Shares Statistics:
For the past three months, ARWR has traded an average of 2.45M shares per day and 3620310 over the past ten days. A total of 135.70M shares are outstanding, with a floating share count of 125.82M. Insiders hold about 7.35% of the company’s shares, while institutions hold 81.10% stake in the company. Shares short for ARWR as of 1764288000 were 11836793 with a Short Ratio of 4.83, compared to 1761868800 on 11784510. Therefore, it implies a Short% of Shares Outstanding of 11836793 and a Short% of Float of 11.310001.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 7.0 analysts currently analyzing and rating the stock of Arrowhead Pharmaceuticals Inc (ARWR).The consensus estimate for the next quarter is -$1.08, with high estimates of $0.08 and low estimates of -$1.55.
Analysts are recommending an EPS of between -$1.55 and -$5.93 for the fiscal current year, implying an average EPS of -$3.16. EPS for the following year is -$4.53, with 9.0 analysts recommending between -$2.98 and -$6.34.
Revenue Estimates
A total of 10 analysts believe the company’s revenue will be $244.84M this quarter.It ranges from a high estimate of $425.29M to a low estimate of $9M. As of. The current estimate, Arrowhead Pharmaceuticals Inc’s year-ago sales were $2.5MFor the next quarter, 10 analysts are estimating revenue of $58.94M. There is a high estimate of $209M for the next quarter, whereas the lowest estimate is $1.8M.
A total of 14 analysts have provided revenue estimates for ARWR’s current fiscal year. The highest revenue estimate was $599.56M, while the lowest revenue estimate was $86M, resulting in an average revenue estimate of $399.8M. In the same quarter a year ago, actual revenue was $829.45MBased on 12 analysts’ estimates, the company’s revenue will be $275.94M in the next fiscal year. The high estimate is $440.1M and the low estimate is $114.2M.
